個案資料
了解個案內容與學習目標，選擇授課教師及使用課程。
Novartis' Sandoz: Between Generics and Pharma
內容大綱
Sandoz, which made a significant investment in bio-similars as a way to differentiate itself from its generic drug industry peers, has to negotiate with its parent company and the innovative pharma division on how best to commercialize its bio-similar portfolio. What is the best way to balance the parenting advantage of Novartis with the unique demands of the generic drug industry?